It seems that the struggle to find a remedy to deal with coronavirus is being overtaken by geopolitical rivalries and prejudice. Not to mention the commercial interests at stake in a market potentially worth up to $100 billion.
Another vaccine has entered the race to rid the world of the Covid-19 pandemic, but unlike the US version, when the team behind the British-produced AstraZeneca product announced its successful preliminary trial results, the company’s shares plummeted in trading on Monday.
Continue reading https://on.rt.com/avq0